Combination Antiretroviral Therapy: How HIV Became a Manageable Chronic Infection

1. Introduction: From Fatal Syndrome to Chronic Disease

When the acquired immunodeficiency syndrome (AIDS) was first characterized in the early 1980s, a diagnosis was effectively fatal. The identification of the human immunodeficiency virus (HIV) as the causative agent by 1983-1984 opened a path toward rational drug design, but the first licensed agent, zidovudine (AZT), given alone in 1987, produced only transient benefit. The decisive advance came in 1996 with the introduction of combination regimens built around protease inhibitors. This approach — later generalized as combination antiretroviral therapy (cART), or highly active antiretroviral therapy (HAART) — can suppress viral replication to levels below the limit of detection and has transformed HIV infection into a manageable chronic condition for people with reliable access to care.

This article reviews the biological logic of combination therapy, the principal drug classes, the evidence that defines the standard regimen, the historical milestones, and the persistent limitations. Throughout, a distinction is drawn between established facts (approved drugs and large randomized trials), early or observational evidence, and matters that remain hypotheses or open questions. Combination antiretroviral therapy is not a cure; the virus persists in a latent reservoir, and lifelong treatment, adherence, toxicity, resistance, and access remain central problems.

2. The HIV Replication Cycle and Druggable Targets

HIV is a retrovirus whose replication cycle presents several discrete, enzymatically distinct steps. Each step has proven amenable to pharmacological blockade, and it is the availability of drugs against multiple independent targets that makes combination therapy possible.

The cycle begins with attachment and entry: the viral envelope glycoprotein gp120 binds the CD4 receptor and a co-receptor (CCR5 or CXCR4), after which gp41 mediates fusion of the viral and cellular membranes. The viral capsid core is then released into the cytoplasm, and reverse transcriptase copies the single-stranded viral RNA genome into double-stranded DNA. The DNA is transported into the nucleus and integrase inserts it into the host chromosome, forming the provirus. Host machinery transcribes new viral RNA, which is translated into polyproteins; protease then cleaves these polyproteins into mature functional proteins as new virions bud from the cell. The capsid protein (p24) also plays essential roles in nuclear import and assembly and, more recently, has become an independent drug target.

Because each step is required for productive replication, inhibiting two or more steps simultaneously imposes a high genetic barrier to escape: the virus would need to acquire multiple independent resistance mutations at once to continue replicating.

3. Classes of Antiretroviral Drugs

3.1. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

NRTIs are prodrugs that must be phosphorylated intracellularly to their active triphosphate forms. As chain-terminating substrate analogues, they compete with natural nucleotides and are incorporated into nascent viral DNA, where they halt further elongation. They act on reverse transcriptase but, because reverse transcriptase also performs DNA-dependent DNA synthesis, they retain activity as part of most regimens. Commonly used agents include tenofovir (as the prodrugs tenofovir disoproxil fumarate, TDF, and tenofovir alafenamide, TAF), emtricitabine (FTC), abacavir (ABC), lamivudine (3TC), and zidovudine (ZDV, AZT). Older members such as stavudine, didanosine, and zalcitabine are no longer recommended because of toxicity. Tenofovir and emtricitabine (or lamivudine) are the backbone of most modern regimens, largely because of their potency, tolerability, and convenient once-daily dosing.

3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

NNRTIs bind allosterically to a hydrophobic pocket on reverse transcriptase, inducing a conformational change that inhibits the enzyme without competing with nucleotides. They do not require intracellular activation. The class includes efavirenz, nevirapine, etravirine, rilpivirine, and doravirine. A defining limitation is the low genetic barrier to resistance: a single point mutation can confer class-wide resistance. NNRTIs remain widely used, particularly rilpivirine in long-acting injectable therapy and doravirine in contemporary once-daily regimens.

3.3. Protease Inhibitors (PIs)

PIs block the viral protease that cleaves the Gag and Gag-Pol polyproteins into mature structural and enzymatic proteins. When protease is inhibited, immature, non-infectious virions are produced. Because the protease active site is highly conserved, PIs generally have a higher genetic barrier to resistance than NNRTIs. Widely used agents include darunavir and atazanavir; lopinavir and older agents are less used now. Most PIs are administered with a low-dose pharmacokinetic booster (ritonavir or cobicistat) to increase exposure. Metabolic adverse effects, including dyslipidemia and insulin resistance, are the main drawbacks.

3.4. Integrase Strand Transfer Inhibitors (INSTIs)

INSTIs block the strand-transfer step of integration, preventing the viral DNA from being covalently joined to the host chromosome. They are potent, well tolerated, and reach suppressive drug levels quickly, which makes them the preferred anchor drug in first-line regimens. The class includes raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. Second-generation INSTIs (dolutegravir, bictegravir, cabotegravir) have a higher genetic barrier to resistance than raltegravir and elvitegravir. Dolutegravir and bictegravir are among the most widely used anchor agents globally; cabotegravir is formulated both as an oral tablet and as a long-acting injectable nanosuspension.

3.5. Entry, Fusion, Capsid, and Attachment Inhibitors

This heterogeneous group acts at steps other than reverse transcription, integration, or proteolysis. Maraviroc is a CCR5 antagonist that blocks co-receptor binding. Enfuvirtide is a fusion inhibitor peptide that interferes with gp41-mediated membrane fusion; it requires twice-daily subcutaneous injection and is used mainly in salvage settings. Fostemsavir is an attachment inhibitor, and ibalizumab is a post-attachment monoclonal antibody. Lenacapavir is a first-in-class capsid inhibitor, available as a long-acting subcutaneous injection for heavily treatment-experienced individuals. These agents are typically reserved for multidrug-resistant or difficult-to-treat cases rather than first-line use.

4. The Standard Regimen: Two NRTIs Plus an INSTI

Contemporary guidelines from major bodies such as the U.S. Department of Health and Human Services, the European AIDS Clinical Society, and the World Health Organization converge on a simple architecture for initial therapy: two NRTIs plus an integrase strand transfer inhibitor. Representative regimens include dolutegravir plus lamivudine (DTG + 3TC) and the fixed-dose combination bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC). Dolutegravir-based regimens are the backbone of WHO-recommended first-line therapy, with TDF/3TC/DTG as a common global option.

Two-drug regimens have also been validated. The GEMINI trials established that dolutegravir plus lamivudine was non-inferior to a three-drug dolutegravir-based regimen in treatment-naive adults (Cahn et al., The Lancet, 2019); the TANGO trial supported this combination for maintenance in virally suppressed patients. Two-drug regimens reduce cumulative drug exposure but are not appropriate for all situations, notably when hepatitis B co-infection, established resistance, or high baseline viral load complicate the picture.

5. The Historical Arc: AZT Monotherapy and the HAART Revolution

Zidovudine was approved by the U.S. Food and Drug Administration in 1987 for the treatment of HIV/AIDS. As monotherapy it reduced mortality modestly in early trials, but its benefit was short-lived because resistant variants emerged rapidly. The lesson — that HIV’s error-prone reverse transcription generates resistance readily under single-drug pressure — shaped the field.

By 1996, the combination of reverse transcriptase inhibitors with newly approved protease inhibitors produced dramatic declines in AIDS-related illness and death in high-income settings. This era is conventionally dated to the 1996 International AIDS Conference in Vancouver and the widespread adoption of triple-drug HAART. The clinical effect was large enough to be visible in population mortality statistics within a few years. The 1996 regimen that became a benchmark combined two NRTIs with a protease inhibitor; subsequent eras replaced the PI with an NNRTI (notably efavirenz) and, later, with an INSTI.

6. Virologic Suppression, CD4 Recovery, and Life Expectancy

The central goal of cART is durable suppression of plasma viral load to below the limit of detection of standard clinical assays, often expressed as fewer than 50 copies per milliliter. When suppression is achieved and maintained, CD4+ T-cell counts typically recover, opportunistic infections become rare, and the risk of progression to AIDS falls sharply. Large cohort studies have found that people who start therapy early and maintain viral suppression approach life expectancies comparable to those of the general population, though a modest excess of morbidity and mortality persists. This residual gap is attributed in part to chronic immune activation and inflammation that persist even under suppressive therapy, to the long-term effects of antiretroviral drugs, and to comorbidities such as cardiovascular, renal, and hepatic disease.

The principle of early initiation was reinforced by the START trial (INSIGHT START Study Group, New England Journal of Medicine, 2015), which randomized patients with CD4 counts above 500 to immediate versus deferred therapy. Immediate initiation reduced serious AIDS-related and non-AIDS-related events, establishing that the benefits of cART extend beyond a fixed CD4 threshold. [Citation details to be verified.]

7. Treatment as Prevention and Undetectable = Untransmittable

One of the most consequential findings in HIV medicine is that effective treatment prevents onward transmission. The HPTN 052 trial randomized serodiscordant couples to early versus delayed antiretroviral therapy and found that early treatment reduced genetically linked partner transmission by approximately 96% (Cohen et al., New England Journal of Medicine, 2011). This result is widely regarded as the foundational evidence for «treatment as prevention.»

The PARTNER and PARTNER2 studies extended this to condomless sex in serodiscordant couples, including gay couples, and recorded no phylogenetically linked transmissions when the HIV-positive partner had an undetectable viral load. On this evidence, the Undetectable = Untransmittable (U=U) consensus statement was issued by the U.S. Centers for Disease Control and Prevention and partner organizations in 2017-2019. It is important to state the boundary precisely: U=U applies to sexual transmission when viral load is durably suppressed to undetectable levels on therapy and does not, on current evidence, extend automatically to all other transmission routes such as needle sharing. [Marked for verification.]

8. Prevention of Mother-to-Child Transmission

Antiretrovirals also prevent vertical transmission. The landmark Pediatric AIDS Clinical Trials Group protocol 076 (ACTG 076) showed in 1994 that zidovudine given during pregnancy, labor, and to the newborn reduced perinatal transmission by roughly two-thirds (Connor et al., New England Journal of Medicine, 1994). With combination regimens and sustained maternal viral suppression, transmission rates in well-resourced settings have fallen to around or below 1%, and WHO programs using combination prophylaxis have achieved large reductions globally. This is one of the clearest confirmed successes in the field.

9. Long-Acting Injectable Therapy

The combination of long-acting injectable cabotegravir and long-acting injectable rilpivirine (marketed as Cabenuva) allows treatment with intramuscular injections every one or two months rather than daily oral pills. The ATLAS, FLAIR, and ATLAS-2M trials demonstrated non-inferiority to daily oral therapy, with ATLAS-2M supporting an every-two-month schedule (Swindells et al., 2020; Orkin et al., 2020; Overton et al., 2021, New England Journal of Medicine). The obvious benefit is convenience and reduced dependence on daily adherence. The constraints are the need for regular clinic visits for injection, injection-site reactions, the requirement for a documented undetectable viral load and absence of relevant resistance before switching, and the risk of resistance if treatment fails while drug levels wane between doses. Long-acting regimens are an option within treatment, not a replacement for the oral standard.

10. Adherence, Resistance, Virologic Failure, and Switching

The potency of modern regimens depends on consistent adherence. Suboptimal adherence allows low-level replication and the emergence of resistance mutations, and the consequences of resistance differ by drug class. NNRTIs and first-generation INSTIs are vulnerable to single mutations, whereas PIs and second-generation INSTIs require multiple mutations, giving them a higher genetic barrier. When virologic failure is detected, guidelines recommend resistance testing and a switch to a regimen containing at least two, and preferably three, fully active agents. Modern fixed-dose combinations have simplified adherence by reducing pill burden to one tablet per day for many patients, but adherence barriers — mental health, substance use, housing instability, stigma, and side effects — are social as much as pharmacological.

11. Global Scale-Up and the 95-95-95 Targets

The global expansion of antiretroviral therapy is one of the largest public health undertakings in history. UNAIDS has set targets that by 2025, 95% of people living with HIV should know their status, 95% of those diagnosed should be on treatment, and 95% of those on treatment should be virally suppressed. Progress has been substantial but uneven, and reaching the final «third 95» — durable suppression — remains the hardest step in many settings. Scale-up depends on affordable generics, strong supply chains, retained patients, and differentiated service delivery models.

12. Limitations and Open Questions

• No eradication. cART does not eliminate the latent reservoir of integrated provirus in resting memory CD4+ T cells. Interrupting therapy leads to viral rebound, so treatment is lifelong.
• Chronic immune activation. Even with undetectable viral load, persistent inflammation and immune activation contribute to cardiovascular, renal, hepatic, and neurologic comorbidities. The mechanisms remain incompletely understood. [Marked for verification.]
• Adherence and retention. The gap between efficacy in trials and effectiveness in practice is driven largely by adherence and by continuity of care.
• Cost and access. Newer agents, long-acting injectables, and novel classes are expensive, and their availability is uneven across countries and payment systems.
• Resistance surveillance. Transmitted and acquired drug resistance requires ongoing monitoring to preserve the effectiveness of first-line regimens.

Whether newer strategies — therapeutic vaccines, broadly neutralizing antibodies, CRISPR-based proviral excision, and «shock and kill» reservoir-reactivation approaches — will yield a functional or sterilizing cure remains an open scientific question. These are, at present, experimental.

13. Conclusion

Combination antiretroviral therapy is the reason HIV infection is now a manageable chronic disease rather than a fatal one. By targeting reverse transcriptase, protease, integrase, and now entry and capsid, clinicians can suppress viral replication to undetectable levels, allow immune recovery, extend life expectancy toward that of the general population, prevent sexual transmission, and nearly eliminate mother-to-child transmission. The standard regimen — two NRTIs plus an integrase inhibitor — is potent, convenient, and widely available in generic form. Yet cART is not a cure. The latent reservoir persists, chronic inflammation continues, and adherence, resistance, cost, and access constrain real-world outcomes. The next frontier is not better suppression alone but approaches that could achieve durable remission without lifelong therapy.

Sources and Key Research Centers

1. National Institute of Allergy and Infectious Diseases (NIAID), NIH — funds and coordinates the clinical trials networks (ACTG, HPTN, IMPAACT) that produced the central treatment and prevention studies cited here.
2. HIVinfo / ClinicalInfo (NIH) — the U.S. Department of Health and Human Services HIV treatment and prevention guidelines, including recommended initial regimens and switching strategies.
3. U.S. Centers for Disease Control and Prevention (CDC), Division of HIV Prevention — epidemiological surveillance and the evidence behind treatment as prevention and U=U.
4. World Health Organization (WHO), Global HIV, Hepatitis and STI Programmes — global treatment guidelines, the DTG-based first-line recommendation, and 95-95-95 targets.
5. UNAIDS — global statistics, treatment targets, and progress reporting.
6. U.S. Food and Drug Administration (FDA) — dockets and approvals for antiretroviral agents, including combination products and cabotegravir/rilpivirine.
7. International AIDS Society (IAS) — conferences, the U=U consensus, and guidance on treatment and cure research priorities.
8. Key publications
   • Connor EM, Sperling RS, Gelber R, et al. «Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.» New England Journal of Medicine, 1994; 331(18): 1173-1180. [Citation details to be verified.]
   • Cohen MS, Chen YQ, McCauley M, et al. «Prevention of HIV-1 infection with early antiretroviral therapy.» New England Journal of Medicine, 2011; 365(6): 493-505. [Citation details to be verified.]
   • INSIGHT START Study Group. «Initiation of antiretroviral therapy in early asymptomatic HIV infection.» New England Journal of Medicine, 2015; 373(9): 795-807. [Citation details to be verified.]
   • Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. «Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.» New England Journal of Medicine, 2020; 382(12): 1112-1123. [Citation details to be verified.]
9. ClinicalTrials.gov — registry records for START, HPTN 052, and long-acting injectable trials.
10. New England Journal of Medicine, The Lancet — primary venues for the landmark HIV treatment trials discussed.

Note: citation identifiers and specific figures are provided where established; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.